Reporte zur Charge ENN6202

Symptomtext

diagnosed with Guillain-Barre Syndrome; This is a spontaneous report from a contactable consumer (patient). A 55 years old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), second dose, via an unspecified route of administration on 02Mar2021 (Batch/Lot Number: ENN6202) (age at vaccination was 54 years old) as dose 2, single for covid-19 immunisation. Medical history included Chrohns, heart disease (2 stints following heart attack), covid-19 (Prior to vaccination). Concomitant medications included infliximab (REMICAID); fluticasone propionate (FLONASE); atorvastatin; colecalciferol (VITAMINE D); clarithromycin (CLARITAB). The patient previously took the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number: EL9269) on 02Feb2021 (age at vaccination was 54 years old) for covid-19 immunisation, Ceftriaxone Sodium, Tazobactam Sodium (BACTRUM T) and experienced allergy. There was no other vaccine in four weeks. The patient was diagnosed with guillain-barre syndrome on 20Sep2021. Event resulted in Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. The patient was hospitalized for guillain-barre syndrome for 12 days. Treatment IVIG was received. The outcome of the event was unknown. Since the vaccination, the patient had not been tested for COVID-19.